Screener
Ocular Therapeutix OCUL Sales & Marketing
Sales & Marketing at other companies
Other financials
Where this comes from
Reported directly by Ocular Therapeutix in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The source filing: Ocular Therapeutix’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 7:28 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055256
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Costs and operating expenses: | ||
| Cost of product revenue | 1,329 | 1,262 |
| Research and development | 66,213 | 42,857 |
| Selling and marketing | 16,577 | 14,148 |
| General and administrative | 20,006 | 16,348 |
| Total costs and operating expenses | 104,125 | 74,615 |
| Loss from operations | (93,340) | (63,917) |
| Other income (expense): |
Item 1. Financial Statements (unaudited)
FAQ
- What is Ocular Therapeutix's sales & marketing?
- Ocular Therapeutix (OCUL) reported sales & marketing of $16.58M in Q1 2026.
- How has Ocular Therapeutix's sales & marketing changed year-over-year?
- Ocular Therapeutix's sales & marketing increased by 17.2% year-over-year, from $14.15M to $16.58M.
- What is the long-term trend for Ocular Therapeutix's sales & marketing?
- Over 4 years (2021 to 2025), Ocular Therapeutix's sales & marketing has grown at a 11.3% compound annual growth rate (CAGR), from $35.19M to $53.92M.
- What does sales & marketing mean?
- Costs of selling products and services including sales force compensation, commissions, marketing campaigns, trade shows, and customer acquisition expenses.
Ask your AI about Ocular Therapeutix's sales & marketing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude